These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33334656)

  • 1. A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis.
    Liu Y; Zhang C; Li B; Yu C; Bai X; Xiao C; Wang L; Dang E; Yang L; Wang G
    J Dermatol Sci; 2021 Feb; 101(2):84-92. PubMed ID: 33334656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
    Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3.
    Yang L; Li B; Dang E; Jin L; Fan X; Wang G
    J Dermatol Sci; 2016 Feb; 81(2):85-92. PubMed ID: 26627723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T cells and IL-17A levels in noninfectious uveitis.
    Guedes MCE; Arroz MJ; Martins C; Angelo-Dias M; Proença RD; Borrego LM
    Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1269-1278. PubMed ID: 32200408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73/AMPK/mTOR pathway.
    Yan K; Xu W; Huang Y; Zhang Z; Huang Q; Xin KZ; Ma Y; Han L
    Br J Dermatol; 2018 Oct; 179(4):896-905. PubMed ID: 29572822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IκBζ is a key player in the antipsoriatic effects of secukinumab.
    Bertelsen T; Ljungberg C; Litman T; Huppertz C; Hennze R; Rønholt K; Iversen L; Johansen C
    J Allergy Clin Immunol; 2020 Jan; 145(1):379-390. PubMed ID: 31622687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hsa_circ_0003738 Inhibits the Suppressive Function of Tregs by Targeting miR-562/IL-17A and miR-490-5p/IFN-γ Signaling Pathway.
    Yang L; Zhang C; Bai X; Xiao C; Dang E; Wang G
    Mol Ther Nucleic Acids; 2020 Sep; 21():1111-1119. PubMed ID: 32871353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The distinct role and regulatory mechanism of IL-17 and IFN-γ in the initiation and development of plaque vs guttate psoriasis.
    Yan K; Han L; Deng H; Fang X; Zhang Z; Huang G; Zheng ZZ; Huang Q; Xu J
    J Dermatol Sci; 2018 Oct; 92(1):106-113. PubMed ID: 30072243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
    Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
    J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
    Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
    J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
    van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.
    Bovenschen HJ; van de Kerkhof PC; van Erp PE; Woestenenk R; Joosten I; Koenen HJ
    J Invest Dermatol; 2011 Sep; 131(9):1853-60. PubMed ID: 21654831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
    Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
    Front Immunol; 2020; 11():1894. PubMed ID: 32973785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
    Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
    JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
    [No Abstract]   [Full Text] [Related]  

  • 17. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.
    Wilsmann-Theis D; Schnell LM; Ralser-Isselstein V; Bieber T; Schön MP; Hüffmeier U; Mössner R
    J Dermatol; 2018 Jul; 45(7):850-854. PubMed ID: 29655177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Th17, Th22, and Th1 cells are increased in psoriasis.
    Kagami S; Rizzo HL; Lee JJ; Koguchi Y; Blauvelt A
    J Invest Dermatol; 2010 May; 130(5):1373-83. PubMed ID: 20032993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-17A contributes to propagation of inflammation but does not impair adipogenesis and/or insulin response, in adipose tissue of obese individuals.
    Pestel J; Chehimi M; Bonhomme M; Robert M; Vidal H; Eljaafari A
    Cytokine; 2020 Feb; 126():154865. PubMed ID: 31629101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.